Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Metformin  COVID-19 treatment studies for Metformin  C19 studies: Metformin  Metformin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Ventilation 54% Improvement Relative Risk ICU admission 56% c19early.org/mf Cousins et al. Metformin for COVID-19 Prophylaxis Is prophylaxis with metformin beneficial for COVID-19? PSM retrospective 4,995 patients in the USA Lower ventilation (p=0.007) and ICU admission (p<0.0001) Cousins et al., medRxiv, doi:10.1101/2022.07.02.22277181 Favors metformin Favors control
Integrative analysis of viral entry networks and clinical outcomes identifies a protective role for spironolactone in severe COVID-19
Cousins et al., medRxiv, doi:10.1101/2022.07.02.22277181 (Preprint)
Cousins et al., Integrative analysis of viral entry networks and clinical outcomes identifies a protective role for.., medRxiv, doi:10.1101/2022.07.02.22277181 (Preprint)
Jul 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
PSM retrospective 64,349 COVID-19 patients in the USA, showing metformin associated with lower ICU admission and mechanical ventilation.
risk of mechanical ventilation, 54.0% lower, OR 0.46, p = 0.007, treatment 2,498, control 2,497, propensity score matching, RR approximated with OR.
risk of ICU admission, 56.0% lower, OR 0.44, p < 0.001, treatment 2,498, control 2,497, propensity score matching, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Cousins et al., 6 Jul 2022, retrospective, USA, preprint, 8 authors.
Contact: cousinsh@stanford.edu, russ.altman@stanford.edu, yuan.luo@northwestern.edu, congle@stanford.edu.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperMetforminAll
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2022.07.02.22277181; this version posted July 6, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Integrative analysis of viral entry networks and clinical outcomes identifies a protective role for spironolactone in severe COVID-19 Henry Cousins1,2,*, Adrienne Sarah Kline3, Chengkun Wang4,5, Yuanhao Qu4,5, Mengdi Wang6, Russ Altman1,4,7,8,*, Yuan Luo3,*, Le Cong4,5,* 1 Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA, USA 2 Medical Scientist Training Program, Stanford University School of Medicine, Stanford, CA, USA 3 Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA 4 Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA 5 Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA 6 Department of Electronic Engineering, Princeton University, Princeton, NJ, USA 7 Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA 8 Department of Bioengineering, Stanford University, Stanford, CA, USA * Correspondence to: cousinsh@stanford.edu (H.C.), russ.altman@stanford.edu (R.A.), Yuan.Luo@northwestern.edu (Y.L.), congle@stanford.edu (L.C.) ABSTRACT Treatment strategies that target host entry factors have proven an effective means of impeding viral entry in HIV and may be more robust to viral evolution than drugs targeting viral proteins directly. High-throughput functional screens provide an unbiased means of identifying genes that influence the infection of host cells, while retrospective cohort analysis can measure the real-world, clinical potential of repurposing existing therapeutics as antiviral treatments. Here, we combine these two powerful methods to identify drugs that alter the clinical course of COVID-19 by targeting host entry factors. We demonstrate that integrative analysis of genomewide CRISPR screening datasets enables network-based prioritization of drugs modulating viral entry, and we identify three common medications (spironolactone, quetiapine, and carvedilol) based on their network proximity to putative host factors. To understand the drugs’ real-world impact, we perform a propensity-score-matched, retrospective cohort study of 64,349 COVID-19 patients and show that spironolactone use is associated with improved clinical prognosis, measured by both ICU admission and mechanical ventilation rates. Finally, we show that spironolactone exerts a dose-dependent inhibitory effect on viral entry in a human lung epithelial cell line. Our results suggest that spironolactone may improve clinical outcomes in COVID-19 through tissue-dependent inhibition of viral entry. Our work further provides a potential approach to integrate functional genomics with real-world evidence for drug repurposing. NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 1 medRxiv preprint doi: https://doi.org/10.1101/2022.07.02.22277181; this version posted July 6, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit